Next Article in Journal
Monoamine Oxidase (MAO) as a Potential Target for Anticancer Drug Design and Development
Next Article in Special Issue
Characterization, Antioxidant and Anti-Inflammation Capacities of Fermented Flammulina velutipes Polyphenols
Previous Article in Journal
Analytical Assessment of Bioelements in Various Types of Black Teas from Different Geographical Origins in View of Chemometric Approach
Previous Article in Special Issue
High Throughput Screening of the NatureBank ‘Marine Collection’ in a Haemonchus Bioassay Identifies Anthelmintic Activity in Extracts from a Range of Sponges from Australian Waters
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Molecules
Volume 26
Issue 19
10.3390/molecules26196018
molecules-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Patient-Derived Tumor Chemosensitization of GKB202, an Antrodia Cinnamomea Mycelium-Derived Bioactive Compound

by
Tsung-Ju Li
1,
Ting-Wei Lin
1,
Shih-Pei Wu
2,
Hsin-Tung Chu
1,
Yu-Hsuan Kuo
1,
Jeng-Fong Chiou
3,4,5,
Long-Sheng Lu
3,6,7,8,* and
Chin-Chu Chen
1,9,10,*
1
Biotech Research Institute, Grape King Bio, Taoyuan 32542, Taiwan
2
CancerFree Biotech Ltd., Taipei City 106, Taiwan
3
Department of Radiation Oncology, Taipei Medical University Hospital, Taipei City 110, Taiwan
4
TMU Research Center of Cancer Translational Medicine, Taipei Medical University, Taipei City 110, Taiwan
5
Department of Radiology, School of Medicine, College of Medicine, Taipei Medical University, Taipei City 110, Taiwan
6
Graduate Institute of Biomedical Materials and Tissue Engineering, College of Biomedical Engineering, Taipei Medical University, Taipei City 110, Taiwan
7
International Ph.D. Program in Biomedical Engineering, College of Biomedical Engineering, Taipei Medical University, Taipei City 110, Taiwan
8
International Ph.D. Program for Cell Therapy and Regenerative Medicine, College of Medicine, Taipei Medical University, Taipei City 11031, Taiwan
9
Department of Food Science, Nutrition, and Nutraceutical Biotechnology, Shih Chien University, Taipei City 104, Taiwan
10
Institute of Food Science and Technology, National Taiwan University, Taipei City 10617, Taiwan
*
Authors to whom correspondence should be addressed.
Molecules 2021, 26(19), 6018; https://doi.org/10.3390/molecules26196018
Submission received: 18 August 2021 / Revised: 29 September 2021 / Accepted: 29 September 2021 / Published: 4 October 2021
(This article belongs to the Special Issue Bioactive Compounds from Nature: New Research and Prospects)
Browse Figures
Versions Notes

Abstract

Oral cancers, hepatocellular carcinoma, and colorectal cancers are the three most common cancers, leading to 18,000 cases of cancer-related mortality in Taiwan per year. To bridge the gap towards clinical translation, we developed a circulating tumor cell (CTC) organoid culture workflow that efficiently expands CTC from patients to test Antrodia Cinnamomea mycelium-derived bioactive compounds. Three ACM-derived bioactive compounds were evaluated for tumor chemosensitization characteristics. Significant and consistent cytotoxic/5-FU sensitizing effects of GKB202 were found on 8 different patient-derived tumors. Acute toxicity profile and hepatic metabolism of GKB202 in rats suggest GKB202 is rapidly cleared by liver and is well tolerated up to the dose of 20 mg/kg. This comprehensive study provides new evidence that liquid fermentation of Antrodia cinnamomea mycelium (ACM) contains bioactive compounds that lead to effective control of CTC, especially when combined with 5-FU. Together, these data suggest ACM-derived GKB202 may be considered for further clinical investigation in the context of 5-FU-based combination therapy.
Keywords: Antrodia Cinnamomea mycelium; ACM; circulating tumor cells; patient-derived organoid; 5-FU Antrodia Cinnamomea mycelium; ACM; circulating tumor cells; patient-derived organoid; 5-FU

Share and Cite

MDPI and ACS Style

Li, T.-J.; Lin, T.-W.; Wu, S.-P.; Chu, H.-T.; Kuo, Y.-H.; Chiou, J.-F.; Lu, L.-S.; Chen, C.-C. Patient-Derived Tumor Chemosensitization of GKB202, an Antrodia Cinnamomea Mycelium-Derived Bioactive Compound. Molecules 2021, 26, 6018. https://doi.org/10.3390/molecules26196018

AMA Style

Li T-J, Lin T-W, Wu S-P, Chu H-T, Kuo Y-H, Chiou J-F, Lu L-S, Chen C-C. Patient-Derived Tumor Chemosensitization of GKB202, an Antrodia Cinnamomea Mycelium-Derived Bioactive Compound. Molecules. 2021; 26(19):6018. https://doi.org/10.3390/molecules26196018

Chicago/Turabian Style

Li, Tsung-Ju, Ting-Wei Lin, Shih-Pei Wu, Hsin-Tung Chu, Yu-Hsuan Kuo, Jeng-Fong Chiou, Long-Sheng Lu, and Chin-Chu Chen. 2021. "Patient-Derived Tumor Chemosensitization of GKB202, an Antrodia Cinnamomea Mycelium-Derived Bioactive Compound" Molecules 26, no. 19: 6018. https://doi.org/10.3390/molecules26196018

APA Style

Li, T.-J., Lin, T.-W., Wu, S.-P., Chu, H.-T., Kuo, Y.-H., Chiou, J.-F., Lu, L.-S., & Chen, C.-C. (2021). Patient-Derived Tumor Chemosensitization of GKB202, an Antrodia Cinnamomea Mycelium-Derived Bioactive Compound. Molecules, 26(19), 6018. https://doi.org/10.3390/molecules26196018

Article Metrics

Back to TopTop